Á¿×Ó¹²Õñ¼ì²â,Quantum resonance detectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¦ÅßÄòÄÒĤÊÔÑé,chick embryo chorioallantoic membrane assayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö·Ö×Ó±êÖ¾Îï,molecular tumor markersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´ÅÈÈÁÆ,magnetic mediated hyperthermiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Gardner×ÛºÏÕ÷,Gardner's syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁÙ´²ÊÔÑéÉè¼Æ,design of clinical trialsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÔ´ÐÔ¹ÇÈí»¯Ö¢,oncogenic osteomalaciaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁÙ´²Ñо¿½øÕ¹,Current clinical research progressÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
PI3K/Akt/mTOR,PI3K/Akt/mTOR signal pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐØÇ»´©´ÌÒýÁ÷,Thoracentesis and drainageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔÐØ»ýÒº,Malignant pleural effusion Double-draining waysÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ìÍÑÑõµ¨ËáÑÜÉúÎï,chenodeoxycholic acid derivativeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾«È·ÖÎÁÆ,accurate therapy of cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹HER2µ¥¿¹,anti-HER2 monoclonal antibodyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ý¼«ÖÎÁÆ,aggressive manage mentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Èý½×ÌÝֹʹ·¨,The three steps analgesic ladder for cancer pain managementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑøѪ½ºÄÒ,Yangxue capsuleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¾±ÇåÊõ,residual / recurrent cervical metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûÖÜÆÚÒÀÀµÐÔ¼¤Ã¸4,CDK 4Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÎËáÂð·È»ºÊÍƬ,morphine hydrochloride sustained-release tabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÒÌ«Äá͸ƤÌù,Fentany transdermal patchÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔÐظ¹Ç»»ýÒº,malignant hydrothorax and seroperitoneumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÃÀ·Æ¿µ,morphine hydrochloride sustained-release tabletÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍâÖÜѪµ¥ºËϸ°û(PBMC),periphera blood mononuclear cell(PBMC)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
СԲϸ°û,Roundlet cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ѪÁ÷¹à×¢ÂÊ,blood flow perfusion rateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ì¥Å̶àëÄ,placenta polypeptideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
º¬²¬·½°¸,platinum containing regimensÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔçÊìȾɫÌåÄý¼¯,premature chromosome condensationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔ½¬Ä¤Ç»»ýÒº,Malignant serous effusionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌØÒìÐÔÊÜÌå,specific receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°×ϸ°û½éËØ2/ͶҩºÍ¼ÁÁ¿,interleukin-2/administration & dosageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÇÖ×Áö/·ÅÉäÐÔºËËØÏÔÏñ,bone neoplasms/radionuclide imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûÅàÑøÒº,culture medium for cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
3H-TdRÊÍ·Å·¨,~ 3H-TdR methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×Ô¿Øֹʹ±Ã,auto-controlled analgesicÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸¹Ä¤ºóÖ×Áö/²¡Àíѧ,retroperitoneal neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·´ÒåSurvivinºËËá,Antisense Survivin RNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÐÀÏÄ껼Õß,middle and old aged patientsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éñ¾ÓªÑøÒò×ÓÊÜÌå,neurotrophic factor receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹Ö×ÁöЧ¹û,Antitumor responseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹Éñ¾Ôª¿¹Ìå,anti-neuronal antibodyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ƥ·ôתÒÆ°©,cutaneous metastatic carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ°°×оƬ¼ì²âϵͳ,protein chip assay systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö¹ÍÂÁÆЧ,antiemetic effectÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûӡƬ,Imprint smearÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÒÌ«ÄáÌù¼Á,Fentanyl SystemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔöÉú¼äƤϸ°û,Reactive mesothelial cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐØÇ»ÄÚ¸øÒ©,chest cavity administrationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ðز¿¶ñÐÔÖ×Áö,thoracic malignant tumourÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÎÓú±ê×¼,curative criteriaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐØÇ»ÄÚ¹à×¢,intrathoracic instillationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Íç¹ÌÐÔ°©Í´,chronic cancerous painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
rhIL-13,recombinant human interleukin-13(rhIL-13)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ѫ˨˨ÈûÖ¢,thromboembolic diseasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áöϸ°û½þÈó,invasion of tumor cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸¹ÅèÇ»,peritoneal and pelvicÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ÷Ç¿ÖÎÁÆ,intensity modulated therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶àÔ·¢ÐÔ°©,Multiple primary cancersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÀÏÄê°©Ö¢,The old cancerousÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐØÇ»ÄÚ×¢Ò©,pleural plenracotomyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Һ̬¼î½ðÊô,liquid alkali metalsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¸ºÎÆ«²î,geometry warpÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò½ÔºÖÐ×ÓÕÕÉäÆ÷,clinical neutron irradiatorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
H_(22)¸Î°©Ï¸°û,H_(22) hepatomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¼Êõ³ÉÊì,technology ripeningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö²¡¶¾,tumorigenic virusesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ù·ÖÀàÆ÷,base classifiersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐÅÏ¢»ñÈ¡ÐÐΪ,information acquirement behaviorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼ÁÁ¿Ñ§ÌØÐÔ,Dosimetric characteristicsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ùÒò×è¶ô,gene repressionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°ÐÏò¶¨Î»,targeted localizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉýÎÂЧӦ,Temperature elevationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔÖ×Áöϸ°û,malignant tumor cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈÏÖªÀú³Ì,cognition processesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°¬Êϸ¹Ë®Áöϸ°û,Ehrlich ascites tumor cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÉÃ׸øҩϵͳ,nanometer drug delivery systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸±Áö×ÛºÏÕ÷,paraneoplatic syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔÖ×Áö¹ÇתÒÆ,malignancy bone metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉÙ¼ûÕ÷Ïó,rare manifestationsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½¡Æ¢ÒæÉö¿ÅÁ£,Jianpiyishen GranulesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼±ÐԷǵÈÈÝÁ¿ÑªÒºÏ¡ÊÍ,Acute non-isovolemic hemedilutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô¤ÆÚÐÔ¶ñÐÄÅ»ÍÂ,anticipatory nausea and vomitingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
UPRT»ùÒò,UPRT geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ǶºÏÃâÒßÊÜÌå,chimeric immune receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Raf¼¤Ã¸Àà,raf kinasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸¨ÖúÕòÍ´,relieve painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ç»ÄÚ»¯ÁÆ,Intracavitary chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ìåλ¹Ì¶¨¼¼Êõ,technique of immobilizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
H22ºÉÁöСÊó,H22 hepatoma-bearing miceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂËÅÝÊ÷ͻ״ϸ°ûÈâÁö,follicular cell sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍÑàÑßÊ/ÍÑà×ऺËËáÄÚÇÐø/Ñõ»¯»¹ÔÒò×Ó-1,Apurinic / apyrimidinic endonuclease / redox factor-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ðز¿·ÅÁÆ,thoracic radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÉÃ×ÔØÌåÒ©Îï,nanocarrier drugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹Ç΢»·¾³,bone microenvironmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²¹Ñª·½,drugs for enriching blood,nourishing blood formulasÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
DNA¾ÛºÏø¦Æ,DNA polymerase ¦ÆÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÌåÄÚ¿¹Ö×Áö»îÐÔ,in vivo efficacyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µòÍöÏÔÏñ,apoptosis imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Æ¢Éö·½,Pi shenfangÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
![](/css/logo.gif)
|